Introduction

This page explains common terminology and legal concepts related to prescription drug injuries. The goal is to help readers understand what pharmaceutical side effects are, how drug-related lawsuits work, and what terms like “adverse events” and “failure to warn” mean in the context of mass tort litigation.

This information is educational only. It is not legal advice, and reading it does not create an attorney-client relationship with Red Bird Legal or any other law firm.

What Is a Pharmaceutical Side Effect?

A pharmaceutical side effect is an unwanted medical effect that happens after a person takes a prescription drug. Side effects can range from mild to severe.

In simple terms: When someone takes a drug to treat one condition, the drug may cause a different problem. That different problem is called a side effect.

Side effects can happen for several reasons. A drug might affect the body in ways beyond its intended use. Some people may have different reactions based on their health, age, or other medications they take. The drug’s ingredients might interact with other substances in the body.

Not everyone who takes a drug experiences the same side effects. Some people have no side effects. Others may have several. The frequency and severity can vary widely based on individual factors.

Adverse Events vs. Side Effects: What Is the Difference?

In medical and legal discussions about drugs, you may hear the term “adverse event.”

An adverse event is any negative health outcome that occurs after a person takes a medication. It is the broader, more formal term used by doctors, researchers, and regulatory agencies.

A side effect is a specific type of adverse event. It is an unwanted effect that is known or suspected to be caused by the drug.

The key difference: All side effects are adverse events, but not all adverse events are necessarily caused by the drug. An adverse event might happen to someone taking a medication, but the event might have been caused by something else entirely, another medication, an underlying condition, or an unrelated health issue.

In lawsuits, attorneys investigate whether an alleged adverse event was actually caused by the drug, or whether other factors played a role.

Understanding Failure to Warn Claims

A failure to warn claim is a common legal theory in pharmaceutical injury litigation.

In simple terms: A pharmaceutical company may have a legal duty to warn doctors and patients about known risks or side effects of their drug. If the company failed to provide an adequate warning or failed to disclose a known risk, a lawsuit may allege that the failure to warn caused injury.

What Manufacturers Must Warn About

Pharmaceutical manufacturers must provide warnings and safety information about:

• Known side effects and their frequency
• Serious or life-threatening risks
• Risks that emerge from clinical trials or post-market surveillance
• Drug interactions (how the drug may react with other medications)
• Contraindications (situations when the drug should not be used)
• Dosage information and how to use the drug safely

What Constitutes an Adequate Warning?

An adequate warning typically includes:

• Clear, accessible language about the risk
• Information about how common the risk is
• Information about how serious the risk is
• Guidance for patients and doctors on how to monitor for the risk
• Information on how to manage or prevent the risk if possible

When Are Warnings Considered Inadequate?

Attorneys investigating pharmaceutical injury claims may examine whether warnings were:

• Missing important safety information
• Buried in dense medical language that patients could not understand
• Placed where patients or doctors were unlikely to see them
• Downplayed or minimized compared to what the company knew about the risk
• Updated too slowly after new safety data emerged

In lawsuits, plaintiffs may allege that an inadequate warning prevented patients and doctors from making fully informed decisions about using the drug.

Black Box Warnings: What Do They Mean?

A black box warning is the strongest safety warning that the U.S. Food and Drug Administration (FDA) can require a pharmaceutical manufacturer to include on a drug’s label.

The name comes from the black border around the warning on the drug’s package insert and prescribing information.

What Does a Black Box Warning Mean?

When the FDA issues a black box warning, it means:

• The drug carries a serious risk of adverse events
• The risk may result in death, serious injury, or serious adverse event
• Healthcare providers and patients need to be aware of this risk before using the drug
• The FDA has determined that the risk is significant enough to warrant the strongest available warning

Why Does the FDA Issue Black Box Warnings?

The FDA issues black box warnings based on:

• Safety data from clinical trials
• Reports of adverse events that happen after the drug is on the market
• Requests from healthcare providers or patient advocacy groups
• Company-submitted safety data

Black Box Warnings Are Not Proof of Liability

It is important to understand: A black box warning does not automatically mean a pharmaceutical company is liable for injuries. A black box warning means the FDA determined a serious risk exists and that patients and doctors need to know about it.

However, if a warning was added after people already used the drug without knowing about the risk, litigation may allege that the delayed warning caused harm.

FDA Adverse Event Reporting (FAERS)

The FDA maintains a system called the Adverse Event Reporting System (FAERS). This database collects reports of adverse events related to drugs, biologics, and other FDA-regulated products.

How FAERS Works

• Healthcare providers, manufacturers, and patients can report adverse events to FAERS
• The FDA reviews these reports to identify patterns or trends
• If a pattern suggests a serious or previously unknown risk, the FDA may take action
• The FDA may require a label change, issue a warning, or restrict how the drug is used

What FAERS Reports Mean

FAERS reports document suspected adverse events. A report in FAERS does not prove that a drug caused an event. It means someone reported that an adverse event occurred in a person taking that drug.

Researchers and regulators analyze FAERS data to identify whether a pattern exists. If many similar reports suggest a link between the drug and a specific adverse event, that may trigger further investigation or regulatory action.

Occupational Hazards vs. Community Exposure in Pharmaceutical Contexts

In mass tort litigation, distinguishing between occupational hazards and community exposure is important. These terms describe different ways people may be exposed to harm related to pharmaceuticals.

Occupational Hazards

Occupational hazard refers to exposure that occurs in a workplace setting, typically during the manufacturing or production of a pharmaceutical product.

Examples include:

• Workers at pharmaceutical manufacturing facilities who are exposed to chemical ingredients or manufacturing byproducts
• Factory workers exposed to ethylene oxide gas (used to sterilize medical devices and some pharmaceutical products)
• Workers at sterilization facilities that use chemical sterilants to prepare medical supplies and pharmaceuticals for distribution
• Employees in pharmaceutical research facilities exposed to experimental compounds

In these cases, the exposure is not to the finished drug itself, but to chemicals, gases, or processes involved in making the drug or related products.

Occupational exposure cases often involve workplace safety regulations and employer liability, in addition to claims about the hazardous substance itself.

Community Exposure

Community exposure refers to exposure that occurs in the general population, outside of an occupational setting.

In the context of pharmaceuticals, community exposure typically means:

• People who take a prescribed medication and experience side effects
• People who are exposed to a drug through over-the-counter use
• People exposed to a drug in a medical setting (such as during surgery or hospitalization)
• Family members exposed to residues or byproducts of a drug taken by someone in the household

In community exposure cases, the focus is on whether the drug caused injury to people who used it as intended, or on whether warnings were adequate for the people actually taking the medication.

Why the Distinction Matters

The distinction matters because:

• Different regulations apply to workplace exposure vs. consumer exposure
• Evidence of harm may be different (occupational exposure data vs. clinical trial data)
• Legal theories may differ (workplace safety claims vs. product liability claims)
• The responsible parties may be different (employer vs. manufacturer vs. healthcare provider)

Common Drug Injury Litigation Terms

Clinical Trial

A clinical trial is a research study in which a new or existing drug is tested in human subjects to determine its safety and effectiveness.

Clinical trials happen in phases:

• Phase 1 trials test safety and dosage in a small group of people
• Phase 2 trials test effectiveness and side effects in a larger group
• Phase 3 trials compare the new drug to existing treatments in a large population
• Phase 4 trials (post-market surveillance) monitor the drug’s effects after it is approved and on the market

Data from clinical trials is a primary source of information about a drug’s known risks.

Post-Market Surveillance

Post-market surveillance is the ongoing monitoring of a drug’s safety after it is approved by the FDA and available to the public.

During post-market surveillance:

• Healthcare providers and patients report adverse events
• The FDA and manufacturer track safety data
• New risks or safety issues may be identified that were not apparent during clinical trials
• The FDA may require label changes or other actions

FDA Approval (510(k) and NDA)

The FDA reviews drugs before they are allowed on the market. There are different approval pathways:

• An NDA (New Drug Application) is used for new chemical entities or new uses of existing drugs
• A 510(k) submission is used for certain medical devices and is a less rigorous pathway than NDA review

All drugs must be found to be safe and effective before FDA approval. However, “safe and effective” means the drug’s benefits outweigh its known risks for its intended use. It does not mean the drug is risk-free or that all possible risks have been identified.

Causation

Causation is a central issue in drug injury litigation. It refers to the question of whether the drug actually caused the alleged injury.

In legal terms, causation typically requires:

• Evidence that the person took the drug
• A temporal relationship (the injury happened after taking the drug, within a timeframe consistent with the drug causing it)
• Medical and scientific evidence that the drug could have caused the injury
• An investigation ruling out other causes

Establishing causation can be complex. Just because someone took a drug and later developed an injury does not automatically mean the drug caused the injury. Other factors such as genetics, lifestyle, other medications, or pre-existing conditions may have played a role.

Statute of Limitations

A statute of limitations is a legal deadline for filing a lawsuit. The deadline varies by state and by the type of claim.

For pharmaceutical injury claims, the statute of limitations may be based on:

• When the injury occurred
• When the person discovered the injury or its connection to the drug
• How long the person was exposed to the drug

Some states follow a “discovery rule,” which means the deadline starts when the person discovered (or reasonably should have discovered) the link between the drug and the injury. Other states use a different calculation.

Missing the statute of limitations deadline means a person loses the right to file a lawsuit, even if they have a valid claim.

FDA Drug Safety Communications and Recalls

The FDA issues drug safety communications when new safety information becomes available. These communications may include:

• Warnings about new risks identified after approval
• Recommendations to change how the drug is used
• Notifications that the FDA is investigating a safety concern
• Announcements of drug recalls or removals from the market

A drug recall or removal from the market does not automatically mean a lawsuit will be successful. However, it may indicate that the FDA determined the drug poses a risk that outweighs its benefits, or that there is a manufacturing or safety problem.

Eligible Injuries in Pharmaceutical Litigation

Different pharmaceutical injury lawsuits focus on different types of injuries. Common categories include:

Cancer

Some pharmaceutical lawsuits allege that a drug increases the risk of cancer. Examples include claims that certain hormonal drugs increase the risk of breast cancer or that other drugs increase the risk of lymphoma.

To establish a connection, attorneys typically review:

• Scientific literature on the drug’s effects
• Clinical trial data
• Post-market adverse event reports
• Expert medical opinions on causation

Cardiovascular Events

Some drugs are alleged to increase the risk of heart attacks, strokes, blood clots, or other cardiovascular problems. Litigation may examine whether the risk was known and disclosed.

Organ Damage

Some drugs are alleged to cause damage to organs such as the liver, kidneys, or pancreas. Cases may examine whether adequate warnings were provided about monitoring for organ damage.

Birth Defects and Pregnancy-Related Injury

Some drugs are alleged to cause birth defects or harm to pregnant women or their developing babies. These cases often examine what was known about the drug’s safety during pregnancy and whether warnings were adequate.

Neurological and Mental Health Effects

Some drugs are alleged to cause neurological side effects, psychiatric symptoms, suicidal thoughts, or other mental health problems. Cases may examine the adequacy of warnings about psychological risks.

How Drug Injury Lawsuits Work

Investigation Phase

Attorneys investigating a pharmaceutical injury claim typically:

• Review the person’s medical records and prescribing history
• Examine the drug’s label, warnings, and package insert
• Research FDA communications and post-market surveillance data
• Review clinical trial data and published research
• Consult medical experts about causation
• Investigate the company’s knowledge of the risk

Case Development

As the case develops, the attorney may:

• File a complaint outlining the allegations
• Exchange documents and information with the opposing party
• Conduct depositions (recorded testimony)
• Retain expert witnesses in relevant fields (medicine, pharmacology, toxicology)
• Research similar cases or prior settlements

Litigation or Settlement

The case may proceed to trial, be resolved through settlement negotiations, or be part of a larger multidistrict litigation (MDL) where many similar claims are consolidated.

Multidistrict Litigation (MDL) and Pharmaceutical Claims

When many people are injured by the same drug, their cases may be consolidated into a Multidistrict Litigation (MDL).

In an MDL:

• Similar lawsuits filed in different courts are transferred to one federal court
• A judge oversees pretrial proceedings for all cases
• Common issues are litigated together, which makes the process more efficient
• Some cases may settle, while others proceed to trial

MDLs allow injured people to have their claims heard while avoiding duplicative litigation.

What This Does Not Guarantee

This page explains general legal concepts and common terminology in pharmaceutical injury litigation. It is important to understand what this does not mean:

• This page does not tell you whether you have a valid claim
• This page does not guarantee any outcome or recovery
• This page does not promise compensation or settlement amounts
• This page does not mean you qualify for litigation
• This page does not mean every person who takes a drug can file a lawsuit
• This page does not mean every reported side effect is actionable

Eligibility for pharmaceutical injury litigation depends on individual facts, including:

• The specific drug you took
• How long you took it
• What injury you developed
• When you discovered the connection between the drug and the injury
• Whether the connection can be established through medical evidence
• Your location and the applicable state law
• The statute of limitations in your state

Subject-to-Change Language

The status of pharmaceutical litigation, FDA regulatory actions, and scientific understanding of drug risks may change as new evidence emerges, court rulings develop, and regulatory guidance evolves.

This information is current as of the date listed below. It should be reviewed regularly, as:

• New drugs are approved and enter the market
• New side effects or risks may be identified for existing drugs
• FDA warnings and safety communications are updated
• Court rulings may change how drug injury cases are evaluated
• Scientific understanding of a drug’s risks may evolve

Information about litigation status, regulatory action, and scientific understanding is subject to change.

Standard Hub Page Disclaimer

This page is for informational purposes only and is not legal advice.

Reading this page or submitting information does not create an attorney-client relationship with Red Bird Legal or any other law firm.

The status of pharmaceutical litigation, FDA regulatory guidance, drug warnings and safety communications, and scientific understanding of drug-related risks may change. Eligibility for pharmaceutical injury litigation depends on individual facts, including the specific drug used, duration of use, diagnosis, timing, location, medical records, and applicable law.

No outcome, settlement amount, compensation, or recovery can be guaranteed.

If you believe you may have been injured by a prescription drug, consider speaking with an attorney to discuss your individual situation and whether a legal claim may exist.

Source Notes

Information on this page is based on:

• U.S. Food and Drug Administration (FDA) regulations and guidance on drug safety and labeling
• FDA Adverse Event Reporting System (FAERS) data and communications
• Federal court dockets and case management orders for active pharmaceutical multidistrict litigations (MDLs)
• Published clinical trial data and post-market surveillance studies
• Peer-reviewed medical and pharmaceutical literature
• FDA drug safety communications and black box warning announcements
• Approved legal intake criteria and case definitions used by attorneys handling pharmaceutical injury litigation
• Occupational Safety and Health Administration (OSHA) materials on workplace chemical exposure

All claims and allegations referenced reflect how lawsuits characterize alleged harms. Allegations are not proven facts without evidence or admission.

Last Updated: July 2026

Next Review: December 2026

This information is subject to change and should be reviewed regularly as litigation, court rulings, regulatory guidance, and scientific understanding evolve.